Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 12/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 11/20 | 0.33 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22455689 | 0.93 | LMNA (0.42) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL16744195 | 0.85 | TRPM5 (0.31) | GABRA1GABRB1 | |
| SCHEMBL25883784 | 0.80 | — | — | |
| SCHEMBL24874192 | 0.80 | — | — | |
| SCHEMBL22304436 | 0.79 | — | — | |
| SCHEMBL24924164 | 0.77 | — | — | |
| SCHEMBL15702906 | 0.76 | — | — | |
| SCHEMBL24253708 | 0.76 | HPGD (0.37) | LMNA | |
| SCHEMBL22304292 | 0.75 | — | — | |
| SCHEMBL24253401 | 0.72 | HPGD (0.37) | LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227474-A1 | COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230069804-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20230009712-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20230008867-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20220048890-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048890-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | LMNA 246/4885TRPA1 4516/4885CHRM1 4664/4885 |
| US-20230008867-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | LMNA 218/4885TRPA1 4510/4885CHRM1 4689/4885 |
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | LMNA 218/4885TRPA1 4510/4885CHRM1 4689/4885 |
| US-20230009712-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | LMNA 246/4885TRPA1 4516/4885CHRM1 4664/4885 |
| US-20230227474-A1 | COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING | RBM17, SF3B1, SF3B5 | LMNA 301/4885TRPA1 4691/4885CHRM1 4792/4885 |
| US-20230069804-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | LMNA 246/4885TRPA1 4516/4885CHRM1 4664/4885 |
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | LMNA 246/4885TRPA1 4516/4885CHRM1 4664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.